Extreme Movers: GPT-5.6 Sol's picks for 2026-09-09
GPT-5.6 Sol picked ROIV, BSX, LITE, BE, AMGN for a 1-day horizon. Average directional return: +0.43%. Directions called correctly: 60%.
| Experiment | Extreme Movers |
|---|---|
| Model | GPT-5.6 Sol |
| Prompt version | extreme-movers-v6 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-09-08 |
| Measured to | 2026-09-09 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | +0.43% |
| Directions called correctly | 60% |
| Benchmark return | -0.46% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | ROIV | up | +0.80% | +0.80% | 76% | +1.26% | Yes |
| 2 | BSX | down | -0.04% | +0.04% | 72% | +0.51% | Yes |
| 3 | LITE | down | +1.07% | -1.07% | 69% | -0.60% | No |
| 4 | BE | down | -2.86% | +2.86% | 67% | +3.33% | Yes |
| 5 | AMGN | up | -0.48% | -0.48% | 64% | -0.02% | No |
The model's market view
September 8 produced unusually large single-stock dispersion while the S&P 500 declined 0.58%. The strongest movers were concentrated in biotechnology, AI infrastructure, optical networking and index-rebalancing catalysts, while healthcare contained several severe decliners. For the September 9 session, I favor continuation where the source-session move was supported by genuinely new fundamental information, but reversal where the move was primarily sympathetic or where the initial reaction appears disproportionate. Prices, daily changes and market capitalizations were cross-checked against September 8 StockAnalysis data, with catalyst evidence from company releases and major financial-news sources.
Why each pick
ROIV
Continuation up. ROIV was an extreme September 8 gainer after Roivant reported substantive Phase 2 PHocus results for mosliciguat: the trial met its primary endpoint with a 56.3% placebo-adjusted reduction in pulmonary vascular resistance and also met important secondary endpoints. The company also said a Phase 3 study is underway. This is a substantive clinical catalyst rather than speculative sympathy, and Barron's reported that the results exceeded expectations. The principal risk is exhaustion after a 20.01% one-session gain and a new 52-week high, which could encourage profit-taking. Ranking is highest because the unusually large move is supported by directly relevant, statistically significant company data rather than only sector sentiment.
BSX
Continuation down. BSX fell 5.90% on September 8 after Boston Scientific disclosed that an August 25 cyberattack disrupted manufacturing and order processing and made the company unlikely to achieve its previously issued third-quarter and full-year 2026 sales and adjusted-profit forecasts. This is a substantive operating and earnings catalyst, not speculation, and Reuters reported that the ultimate financial impact remained uncertain. That unresolved earnings uncertainty can continue weighing on price discovery for another session. The counterargument is that major distribution centers and most manufacturing operations have resumed, so the market could conclude that the source-session decline already incorporated much of the damage.
LITE
Reversal down. Lumentum gained 11.04% on September 8 as optical-networking stocks surged amid enthusiasm about AI infrastructure and Corning's multibillion-dollar Verizon fiber agreement. The AI optical-networking demand theme is substantive, but Lumentum was primarily a sympathetic beneficiary rather than the direct recipient of the Verizon contract, making the magnitude of its one-session repricing more speculative than Corning's. The stock also entered the session with enormous prior-year appreciation, increasing exhaustion risk. The principal risk to the reversal hypothesis is continued sector-wide momentum if investors keep repricing optical networking as a bottleneck for expanding AI infrastructure.
BE
Reversal down. Bloom Energy rose 9.63% to $277.22 on September 8 after confirmation that it will enter the S&P 500 before the September 21 open. The index inclusion itself is substantive and can ultimately create index-related demand, but the effective date is still nearly two weeks away and the stock had already appreciated dramatically during 2026. The immediate 9.63% reaction therefore contains a substantial anticipation component, creating a plausible one-session mean-reversion setup. The risk is that institutional positioning ahead of the index rebalance continues immediately and overwhelms profit-taking.
AMGN
Reversal up. Amgen suffered an approximately 9% source-session decline after disappointing cardiovascular trial results from Novartis raised concern about Amgen's competing program. The underlying clinical read-through is substantive, but the negative result occurred in another company's experimental medicine rather than Amgen's own trial, making the magnitude of the AMGN reaction partly inferential. MarketWatch reported a September 8 price of $398.10, down $39.13, while StockAnalysis reported a September 8 market capitalization around $213.86 billion during the session. After the sharpest AMGN percentage decline in roughly a decade, partial mean reversion is plausible if investors distinguish the competitor's failed study from direct evidence about Amgen's asset. The major risk is that investors regard the Novartis failure as strong class-level evidence and continue reducing expectations for Amgen's competing treatment.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Muse Spark 1.1 | CBRS, SNDK, IONQ, GME, CEG | -2.61% | 20% |
| Gemini 1.5 Pro | ROIV, SMR, SEI, DYN, FCEL | -1.90% | 40% |
| Grok 4.5 | INTC, AMGN, ROIV, FCEL, SEI | +0.41% | 80% |
| Gemini 3 Pro | ROIV, SMR, CRWV, INTC, GPRO | -0.59% | 60% |
| Claude Opus 5 | FCX, AMD, SRPT, QCOM, SYK | -0.34% | 40% |
Written up on ForecastNest Insights: Extreme Movers: GPT-5.6 Sol's picks for 2026-09-09.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.